
The DFG-funded Research Training Group (RTG) 3095 “Protective and pathogenic antibody responses at barrier organs” is a collaborative doctoral programme jointly organized by the University of Lübeck and Kiel University – two modern and research-intensive universities with strong profiles in medicine, molecular biology, and the life sciences. Their study programmes have consistently achieved top positions in the CHE Ranking, the most comprehensive evaluation of study programmes at German universities.
Immunological barrier organs such as the skin, intestine, and lungs are continuously exposed to commensal microorganisms, pathogens, and environmental allergens. As a result, infections as well as allergic and autoinflammatory disorders at these mucosal interfaces are frequent and represent a significant burden to public health. Antibody-mediated immune responses play a central role in maintaining homeostasis at these sites: they contribute to the control of pathogen invasion, the regulation of gut microbiota, and the initiation and modulation of allergic reactions, while also exerting regulatory functions that can downregulate inflammation.
The overarching goal of RTG 3095 is to elucidate the mechanisms by which B cell responses are initiated, maintained, and contribute to either immunoprotection or immunopathogenesis at these immunological barrier sites. To achieve this, the programme employs state-of-the-art experimental approaches, including single-cell sequencing, spatial transcriptomics, and advanced molecular and immunological techniques. Doctoral researchers will benefit from a structured 4-year training programme that integrates cutting-edge research with comprehensive training opportunities.
Within this framework, the subproject P10 “Diet-dependent metabolic, regulatory and mitochondrial genomic states of B cell memory”, led by Prof. Patrick Maschmeyer at the Institute for Systemic Inflammation Research (ISEF) https://isef-luebeck.de/en/meet-the-lab/maschmeyer-lab-6, University of Lübeck, is seeking a PhD Candidate to start on November 1, 2026. The position is initially limited until October 31, 2030.
We look forward to receiving your application by October 14, 2030, quoting reference number 29293.
Please include the following documents with your application: A motivation letter (maximum one page), A curriculum vitae (including a list of publications, if applicable), Certificates and transcripts of your previous university degrees (BSc/MSc, including transcripts of records), at least one letter of recommendation, Names and email addresses of two potential references.
Among the written applications, suitable candidates will be invited for interviews in October 2026.
For further information, please contact: Prof. Patrick Maschmeyer, ISEF Lübeck – Maschmeyer Lab, Email: Patrick.Maschmeyer@uni-luebeck.de

The University Hospital Schleswig-Holstein (UKSH) with its locations in Kiel and Lübeck is one of the largest medical care centers in Europe. It serves to warrant maximum medical care in the northernmost federal state and guarantees medical-technical care at the highest level, especially for patients who require highly differentiated diagnosis and therapy. The unique feature of university medicine is the interaction of health care, research and teaching with the result that scientific findings flow directly into the health system. The UKSH maintains the entire spectrum of medicine and multidisciplinary centers, cares for patients with rare diseases and extreme medical costs, operates university outpatient clinics and provides emergency care. The UKSH is the only maximum provider in Schleswig-Holstein. With 16,000 employees in over 85 clinics and institutes, UKSH is the largest employer and training provider in Schleswig-Holstein. Strategic personnel development, corporate health management and the certified compatibility of work and family life are integral parts of the corporate culture.
Imprint:
https://www.uksh.de/Impressum.html
Data protection:
https://www.uksh.de/privacy.html#socialmedia